DK0913155T3 - Farmaceutisk formulering til behandling af leverlidelser - Google Patents

Farmaceutisk formulering til behandling af leverlidelser

Info

Publication number: DK0913155T3
Authority: DK; Denmark
Prior art keywords: pharmaceutical formulation; treatment; liver disorders; carotene; coenzyme
Prior art date: 1997-10-24

Application number

DK98308654T

Other languages

English (en)

Inventor

Bent Henriksen

Original Assignee

Pharma Nord Aps

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-10-24

Filing date

1998-10-22

Publication date

2002-06-10

1998-10-22 Application filed by Pharma Nord Aps filed Critical Pharma Nord Aps

2002-06-10 Application granted granted Critical

2002-06-10 Publication of DK0913155T3 publication Critical patent/DK0913155T3/da

Links

239000008194 pharmaceutical composition Substances 0.000 title abstract 2
208000019423 liver disease Diseases 0.000 title 1
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 2
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 abstract 1
208000008439 Biliary Liver Cirrhosis Diseases 0.000 abstract 1
208000033222 Biliary cirrhosis primary Diseases 0.000 abstract 1
ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 abstract 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
208000012654 Primary biliary cholangitis Diseases 0.000 abstract 1
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 abstract 1
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 abstract 1
OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 abstract 1
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 abstract 1
235000010323 ascorbic acid Nutrition 0.000 abstract 1
229960005070 ascorbic acid Drugs 0.000 abstract 1
239000011668 ascorbic acid Substances 0.000 abstract 1
TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 abstract 1
235000013734 beta-carotene Nutrition 0.000 abstract 1
239000011648 beta-carotene Substances 0.000 abstract 1
229960002747 betacarotene Drugs 0.000 abstract 1
235000017471 coenzyme Q10 Nutrition 0.000 abstract 1
ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 abstract 1
229940110767 coenzyme Q10 Drugs 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
229930182817 methionine Natural products 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
229910052711 selenium Inorganic materials 0.000 abstract 1
239000011669 selenium Substances 0.000 abstract 1
229960001295 tocopherol Drugs 0.000 abstract 1
239000011732 tocopherol Substances 0.000 abstract 1
235000019155 vitamin A Nutrition 0.000 abstract 1
239000011719 vitamin A Substances 0.000 abstract 1
229940045997 vitamin a Drugs 0.000 abstract 1
OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Inorganic Chemistry (AREA)
Physical Education & Sports Medicine (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Neurosurgery (AREA)
Gastroenterology & Hepatology (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK98308654T 1997-10-24 1998-10-22 Farmaceutisk formulering til behandling af leverlidelser DK0913155T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9722361.4A GB9722361D0 (en)	1997-10-24	1997-10-24	Pharmaceutical formulation for treating liver disorders

Publications (1)

Publication Number	Publication Date
DK0913155T3 true DK0913155T3 (da)	2002-06-10

Family

ID=10820956

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK98308654T DK0913155T3 (da)	1997-10-24	1998-10-22	Farmaceutisk formulering til behandling af leverlidelser

Country Status (7)

Country	Link
US (1)	US6136859A (da)
EP (1)	EP0913155B1 (da)
JP (1)	JPH11199477A (da)
AT (1)	ATE214609T1 (da)
DE (1)	DE69804281T2 (da)
DK (1)	DK0913155T3 (da)
GB (2)	GB9722361D0 (da)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2782642B1 (fr) *	1998-08-31	2001-12-07	Xavier Forceville	Utilisation du selenium pour le traitement de patients atteints d'un syndrome de reponse inflammatoire systemique (sirs), et composition pour la mise en oeuvre du traitement
US6805880B1 (en) *	1999-08-20	2004-10-19	Ferrosan A/S	Pharmaceutical delivery system for vitamin C and vitamin E and use of a combination of vitamin C and E for preventing or treating conditions involving oxidative stress
WO2001026646A1 (en) *	1999-10-08	2001-04-19	Pharmnseas, Inc.	NUTRACEUTICAL PRODUCTS CONTAINING SAMe AND DIETARY SUPPLEMENTS AND METHOD OF MANUFACTURING AND USE THEREOF
NZ509803A (en) *	2000-02-09	2001-08-31	Paul A	Treatment of fibromyalgia with ubiquinone 10 and succinic acid
AT412758B (de) *	2000-06-05	2005-07-25	Vis Vitalis Lizenz & Handels	Verwendung einer selenithältigen lösung zur behandlung viraler erkrankungen
FR2813762B1 (fr) *	2000-09-14	2003-09-12	Boiron	Complement nutritionnel absorbable integrant du soja
US6995166B1 (en)	2000-09-27	2006-02-07	Everett Laboratories, Inc.	Method and composition for supplementation of nutritional deficiencies in renal patients
US7696219B2 (en) *	2000-09-27	2010-04-13	Everett Laboratories, Inc.	Method and composition for supplementation of nutritional deficiences in renal patients
GB0101459D0 (en) *	2001-01-19	2001-03-07	Uni Vite Exp Ltd	Nutritional composition
US6596762B2 (en) *	2001-05-17	2003-07-22	The Regents Of The University Of Colorado	Antioxidant compositions and use for treatment of hepatic steatosis and steatohepatitis
US6660293B2 (en)	2001-06-29	2003-12-09	Everett Laboratories, Inc.	Compositions and methods for prophylactic and therapeutic supplementation of nutrition in subjects
US6759061B2 (en) *	2001-08-31	2004-07-06	Renew Life, Inc.	Liver function improvement formulation
US7560123B2 (en)	2004-08-12	2009-07-14	Everett Laboratories, Inc.	Compositions and methods for nutrition supplementation
AT412703B (de)	2001-12-04	2005-06-27	Vis Vitalis Lizenz & Handels	Verwendung von selenithältigen präparaten zur topischen oder bukkalen anwendung
AU2003261147A1 (en) *	2002-07-12	2004-02-02	University Of Rochester	Use of amino acids for treatment of various conditions
US6814983B2 (en) *	2002-12-10	2004-11-09	Everett Laboratories, Inc.	Compositions and methods for nutrition supplementation
US8617617B2 (en) *	2002-12-10	2013-12-31	Everett Laboratories, Inc.	Methods and kits for co-administration of nutritional supplements
US9174176B2 (en)	2003-01-09	2015-11-03	Disperse Systems, Inc.	Ultrasonic dispersion apparatus, system, and method
WO2005023274A1 (en) *	2003-09-05	2005-03-17	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
AU2004285450B2 (en) *	2003-10-20	2010-01-14	Gregory K. Frykman	Zeolite molecular sieves for the removal of toxins
JP4971597B2 (ja) *	2005-03-23	2012-07-11	東海物産株式会社	抗酸化組成物
WO2005120479A1 (en) *	2004-06-09	2005-12-22	Gpc Biotech Ag	Use of selenium or a selenium salt and a retinoid acid or a retinoid in the treatment of viral hepatitis c
CN1997403A (zh) *	2004-07-13	2007-07-11	奥里迪斯生物医学研究及开发有限责任公司	靶向线粒体的抗氧化剂在治疗肝病和上皮癌中的用途
US20080063730A9 (en) *	2004-07-29	2008-03-13	Giordano John A	Methods for prophylactic and therapeutic nutritional supplementation
US8101587B2 (en)	2004-08-12	2012-01-24	Everett Laboratories, Inc.	Kits for nutrition supplementation
RU2433819C2 (ru) *	2004-11-09	2011-11-20	Хилл'С Пет Ньютришн, Инк.	Применение антиоксидантов для модуляции генов
AU2005322887B2 (en)	2004-12-30	2010-03-11	Hill's Pet Nutrition, Inc.	Methods for enhancing the quality of life of a senior animal
US8252742B2 (en)	2004-12-30	2012-08-28	Hill's Pet Nutrition, Inc.	Methods for enhancing the quality of life of a senior animal
EP1844006A2 (en) *	2005-01-05	2007-10-17	Magd Ahmed Kotb Abdalla	Taurine synthesis, production and utility as a medicine
WO2006092449A2 (en)	2005-03-02	2006-09-08	Metanomics Gmbh	Process for the production of fine chemicals
WO2006104154A1 (ja) *	2005-03-29	2006-10-05	Kaneka Corporation	肝臓中蛋白質分解酵素の発現及び活性を高める組成物
ES2619303T3 (es)	2005-06-01	2017-06-26	Edison Pharmaceuticals, Inc.	Productos terapéuticos redox activos para el tratamiento de enfermedades mitocondriales y otras afecciones y modulación de biomarcadores energéticos
NZ540958A (en)	2005-06-27	2007-11-30	Agres Ltd	Veterinary formulation for injectable administration of selenomethionine for production of selenium-rich foods
JPWO2007004613A1 (ja) *	2005-07-01	2009-01-29	味の素株式会社	炎症性腸疾患治療薬及びＴＮＦ−α産生抑制剤
SI1933821T1 (sl) *	2005-09-15	2020-11-30	Ptc Therapeutics, Inc.	Repne variante redoks-aktivnih terapevtikov za zdravljenje mitohondrijskih bolezni in drugih bolezni ter modulacijo energijskih biooznačevalcev
EP1797861A1 (en) *	2005-12-16	2007-06-20	KPSS-Kao Professional Salon Services GmbH	Composition for the permanent shaping of human hair
US20070208086A1 (en) *	2006-02-15	2007-09-06	The Regents Of The University Of California	Ubiquinone analogs and methods of use
WO2007100652A2 (en)	2006-02-22	2007-09-07	Edison Pharmaceuticals, Inc.	Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US20070248547A1 (en) *	2006-03-23	2007-10-25	The Regents Of The University Of California	Cascade macromolecular contrast agents for medical imaging
EP2011478A1 (en) *	2007-06-26	2009-01-07	KPSS-Kao Professional Salon Services GmbH	Composition for the permanent shaping of human hair
EP2011479A1 (en) *	2007-06-26	2009-01-07	KPSS-Kao Professional Salon Services GmbH	Composition for the permanent shaping of human hair
EP2011543A1 (en) *	2007-06-26	2009-01-07	KPSS-Kao Professional Salon Services GmbH	Composition for the permanent shaping of human hair
MX363223B (es)	2008-09-10	2019-03-15	Bioelectron Tech Corp	Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox.
AT511159A1 (de)	2011-02-16	2012-09-15	Selo Medical Gmbh	Pharmazeutische zusammensetzungen enthaltend selenit- oder selenathältige verbindungen
US8183227B1 (en)	2011-07-07	2012-05-22	Chemo S. A. France	Compositions, kits and methods for nutrition supplementation
LV14461B (lv) *	2011-09-15	2012-07-20	Paula Stradiņa Klīniskā Universitātes Slimnīca, Vsia	Līdzeklis efektīvai augsta glutamāta līmeņa pazemināšanai asinīs
US8168611B1 (en)	2011-09-29	2012-05-01	Chemo S.A. France	Compositions, kits and methods for nutrition supplementation
US9770421B2 (en) *	2013-03-15	2017-09-26	Indanio Bioscience Inc.	Uses for idebenone and related benzoquinones in metabolic disorders and other PPAR α/γ related diseases and conditions
US10703701B2 (en)	2015-12-17	2020-07-07	Ptc Therapeutics, Inc.	Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
MX2019009841A (es) *	2017-02-16	2020-01-30	Arena Pharm Inc	Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
US20210030840A1 (en) *	2019-02-01	2021-02-04	Myos Rens Technology Inc.	Methods and Compositions for Improving Quality of Life and Increasing Activity in Aging and Chronically Ill Mammals
WO2020160113A1 (en) *	2019-02-01	2020-08-06	Myos Rens Technology Inc.	Egg yolk powder for improving quality of life and increasing activity in aging and chronically ill mammals
JP7474599B2 (ja) *	2020-02-03	2024-04-25	小林製薬株式会社	経口組成物
JP7474598B2 (ja) *	2020-02-03	2024-04-25	小林製薬株式会社	経口組成物
RU2742414C1 (ru) *	2020-06-16	2021-02-05	Владимир Сергеевич Понамарёв	Препарат комплексный с гепатопротекторной активностью для крупного рогатого скота

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE8105887L (sv) *	1981-10-06	1983-04-07	Erland Johansson	Blandning for human tillforsel av selen som sparemne
IT1252717B (it) *	1991-06-18	1995-06-26	Ist Fisioterap Ospitalroma	Preparato farmaceutico da utilizzare quale trattamento coadiuvante della dermatite seborroica anche in soggetti hiv positivi
DE19509354A1 (de) *	1994-12-08	1996-06-13	Klett Loch Lore M	Kombinationspräparat zur Förderung des Haarwachstums und ggf. des Haut- und Nagelwachstums sowie zur Verhinderung bzw. zur Beseitigung von Haarausfall
AU724620B2 (en) *	1996-01-16	2000-09-28	Sokol, Ronald J Dr.	Use of antioxidant agents to treat cholestatic liver disease
US5895652A (en) *	1996-07-29	1999-04-20	Longevity Institute International	Method of metabolic adjuvanation and cellular repair
DE19653100A1 (de) *	1996-12-19	1998-07-23	Adolf Metz	Magnetkapseln mit Milchzucker für Darm, alle Organe und Allgemeinbefinden (als Nahrungsergänzung)
CA2280093A1 (en) *	1997-02-04	1998-08-06	John V. Kosbab	Compositions and methods for prevention and treatment of vascular degenerative diseases

1997
- 1997-10-24 GB GBGB9722361.4A patent/GB9722361D0/en not_active Ceased
1998
- 1998-10-22 GB GB9823038A patent/GB2330531B/en not_active Expired - Fee Related
- 1998-10-22 EP EP98308654A patent/EP0913155B1/en not_active Expired - Lifetime
- 1998-10-22 DK DK98308654T patent/DK0913155T3/da active
- 1998-10-22 AT AT98308654T patent/ATE214609T1/de not_active IP Right Cessation
- 1998-10-22 DE DE69804281T patent/DE69804281T2/de not_active Expired - Fee Related
- 1998-10-23 US US09/177,555 patent/US6136859A/en not_active Expired - Fee Related
- 1998-10-26 JP JP10304137A patent/JPH11199477A/ja active Pending

Also Published As

Publication number	Publication date
GB9722361D0 (en)	1997-12-17
GB2330531A (en)	1999-04-28
GB9823038D0 (en)	1998-12-16
US6136859A (en)	2000-10-24
DE69804281T2 (de)	2002-10-24
EP0913155B1 (en)	2002-03-20
GB2330531B (en)	2002-06-05
EP0913155A2 (en)	1999-05-06
JPH11199477A (ja)	1999-07-27
ATE214609T1 (de)	2002-04-15
EP0913155A3 (en)	1999-09-01
DE69804281D1 (de)	2002-04-25

Publication	Publication Date	Title
DK0913155T3 (da)	2002-06-10	Farmaceutisk formulering til behandling af leverlidelser
PL377285A1 (pl)	2006-01-23	Podstawione pochodne pirolo-pirazolowe jako inhibitory kinazy
DE69804743D1 (de)	2002-05-16	Pyrazolo[4,3-d]pyrimidin-Derivate und diese enthaltende pharmazeutische Zubereitungen
DK0959888T3 (da)	2001-11-05	Anvendelse af det chelerende middel clioquinol til fremstillingen af et farmaceutisk præparat til behandlingen af Alzheimer's sygdom
NO20002217L (no)	2000-07-18	Cyclopentan-heptansyre, 2-heteroarylalkenylderivater som terapeutiske midler
DK0624595T3 (da)	1999-05-17	Nor-galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelse af disse forbindelser som lægemidler
DK1195159T3 (da)	2006-10-02	Terapeutisk kombination af ascorbat med lysin og arginin til forebyggelse eller behandling af cancer
DK0603649T3 (da)	1996-11-04	Substituerede 4-phenyl-pyridoner og 4-phenyl-2-alkoxypyridiner som HMG-CoA-reduktase-inhibitorer
ATE212837T1 (de)	2002-02-15	Pharmazeutische zubereitung zur behandlung akuter rhinitiden, enthaltend sympthomimeticum und pantothenol und/oder pantothensäure
ES2136252T3 (es)	1999-11-16	Tratamiento de enfermedades causadas por trastornos de la glandula sebacea mediante el uso de inhibidores de acil coa colesterol acil transferasa.
UY27338A1 (es)	2003-10-31	Nuevos derivados de ácido sulfónico
ATE433753T1 (de)	2009-07-15	Zusammensetzung von prostaglandin-i-derivaten mit verzoegerter abgabe
ATE174221T1 (de)	1998-12-15	Behandlung von pankreaskrankheit mit 15-keto- prostaglandin e-derivaten
DK0620002T3 (da)	1997-04-01	Fast farmaceutisk doseringsform og fremgangsmåde til formindskelse af afslidning
NO961547D0 (no)	1996-04-18	Flavinderivater som anti-virusmidler
DE69821815D1 (de)	2004-04-01	Thiocolchicin-Derivate mit entzündungshemmender und muskelrelaxierender Wirkung
ES2045348T3 (es)	1994-01-16	Metodo para preparar derivados de lactamimida para el tratamiento o la prevencion de paludismo farmaco-resistente.
MX9401080A (es)	1994-08-31	Compuestos heteroaromaticos.
ATE172721T1 (de)	1998-11-15	Aminosäurederivate und ihre verwendung als enkephalinase-inhibitoren
DZ2202A1 (fr)	2002-12-03	Procédé de préparation d'énantiomères purs d'acides cyclo-alcano-indol-azaindol-et pyrimido (1,2-a) indol-carbocyclique et leurs dérivés actives.
MX9702259A (es)	1997-06-28	Derivados de quinoxalina utiles en terapia.
AU7777794A (en)	1995-05-25	Melatonin derivatives for use in treating sleep disorders
ATE555674T1 (de)	2012-05-15	Zusammensetzung mit der reduzierten form von coenzym q10 und carotenoid-verbindung
ATE19234T1 (de)	1986-05-15	Polyenverbindungen, ihre herstellung und diese verbindungen enthaltende pharmazeutische praeparate.
DE69707964D1 (de)	2001-12-13	Multiantioxidant enthaltendes Arzneimittel